The world’s first hexavalent rotavirus vaccine is approved for marketing

August 25, 2025 Source: drugdu 117

Recently, Sinopharm Group China National Biotec Group Wuhan Biological ProductsThe Institute's oral hexavalent, reassortant, live attenuated rotavirus vaccine (Vero cell-based) (trade name: Wushengerlunbao®) has been officially approved for marketing by the National Medical Products Administration. This product, the world's first and most expensive rotavirus vaccine, is a Class 1 new biological drug for preventive use in China and is primarily used to prevent acute gastroenteritis in infants and young children caused by rotavirus